Travere Therapeutics Projects $3 Billion in FILSPARI Sales by 2033 Amid Patent Extensions
Travere Therapeutics (TVTX) has announced long-term revenue projections for its product FILSPARI, targeting annual sales of $3 billion by the year 2033. This growth trajectory is supported by extended patent protections that are expected to remain in effect until 2037, providing a significant window of market exclusivity. During the Q3 2026 earnings call, CEO Dr. Eric Dube reported strong operational execution and momentum for the company. He also addressed an upcoming leadership transition, noting that he will step down in December and is working closely with his successor, Bradley, to ensure a smooth handover.
Tickers: $TVTX
Topics: CEO succession earnings call executive leadership change
Read the full article at Seeking Alpha
Part of the story Travere Therapeutics Projects $3 Billion in FILSPARI Sales by 2033 Amid Patent Extensions (2 articles)